Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
43.4M
-
Number of holders
-
80
-
Total 13F shares, excl. options
-
14.9M
-
Shares change
-
+875K
-
Total reported value, excl. options
-
$39.3M
-
Value change
-
+$2.54M
-
Put/Call ratio
-
0.25
-
Number of buys
-
35
-
Number of sells
-
-25
-
Price
-
$2.64
Significant Holders of Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE) as of Q4 2023
91 filings reported holding CUE - Cue Biopharma, Inc. - Common Stock, $0.001 par value per share as of Q4 2023.
Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE) has 80 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 14.9M shares
of 43.4M outstanding shares and own 34.29% of the company stock.
Largest 10 shareholders include Slate Path Capital LP (2.4M shares), BlackRock Inc. (2.34M shares), VANGUARD GROUP INC (2.13M shares), Bleichroeder LP (1.76M shares), GEODE CAPITAL MANAGEMENT, LLC (813K shares), STATE STREET CORP (684K shares), Robertson Stephens Wealth Management, LLC (479K shares), DIMENSIONAL FUND ADVISORS LP (458K shares), NORTHERN TRUST CORP (381K shares), and Monaco Asset Management SAM (342K shares).
This table shows the top 80 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.